|Videos|December 7, 2022
Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer
Continuing her discussion, Kathleen highlights the most common adverse events she sees in patients treated with chemotherapy for advanced endometrial cancer who are unfit for surgery.
Advertisement
Episodes in this series
Advertisement
Related to this article
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in ovarian and endometrial cancer.
Selinexor maintenance failed to significantly improve PFS vs placebo in TP53 wild-type advanced or recurrent endometrial cancer in the phase 3 XPORT-EC-042 trial.
Advertisement
Advertisement
Trending on OncLive
1
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
2
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
3
Long-Term Follow-Up Confirms Tivozanib Monotherapy Efficacy in 2L/3L mRCC
4
Colorectal Cancer Isn't the Only Gastrointestinal Cancer Rising in Young Adults
5